EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Oral Mucositis as a Predictor of Systemic Complications and Mortality in Breast Cancer Patients Treated with Antibody–Drug Conjugates: A Real-World Cohort Study

Kiera Kavcic, Zak Ahmed, Minu Ponnamma Mohan, Vipanchika Satheeshkumar, Joel Brian. Epstein, Parikshit Padhi, Roberto Pili, Poolakkad S. Satheeshkumar

Reports · 2026-11-11 · 9 (4) · 391

DOI: 10.3390/reports9040391 ↗
AbstractBibliografische Angaben

Abstract

Background/Objectives: Oral mucositis (OM) is a recognized toxicity of antibody–drug conjugates (ADCs), but its long-term systemic implications are unknown. We assessed long-term systemic complications and mortality associated with OM in patients with breast cancer treated with monoclonal antibodies and antibody–drug conjugates (mADCs). Materials and Methods: This retrospective cohort study used TriNetX data from 88 healthcare organizations. Adults with breast cancer receiving mADCs with (n = 1784) or without (n = 61,616) OM (ICD-10-CM K12.31) were 1:1 propensity score-matched on race, external causes of morbidity, ECOG performance status, and body mass index (1784 per cohort). Outcomes included volume depletion, fluid/electrolyte disorders, respiratory and circulatory disease, malaise/fatigue, pain, dysphagia, and all-cause mortality, assessed from 1 day after the index event using risk differences, Kaplan–Meier analysis, and Cox hazard ratios (HRs). Results: Patients with OM had higher risks of fluid/electrolyte disorders (39.1% vs. 32.1%), respiratory disease (48.5% vs. 39.0%), circulatory disease (63.7% vs. 51.2%), pain (16.1% vs. 11.7%), dysphagia (10.4% vs. 8.2%), and mortality (26.1% vs. 19.3%), with HRs (no OM vs. OM) of 0.664–0.753 (log-rank p ≤ 0.002 for all). Volume depletion and malaise/fatigue showed no significant absolute risk differences but significant survival differences (HR 0.824 and 0.855). Recurrent event counts did not differ. Conclusions: In patients with breast cancer treated with mADCs, OM was associated with greater long-term systemic morbidity and mortality after propensity score matching. OM may serve as a marker of systemic vulnerability, supporting routine oral health assessment and oncology–dentistry collaboration during ADC therapy, with implications for toxicity management as ADC use expands.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →